Selected research
Industry Research
Opioids Agonist Drugs Industry Research Report 2026
Market perspective
The global Opioids Agonist Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Opioids Agonist Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Opioids Agonist Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Opioids Agonist Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Opioids Agonist Drugs include Janssen Pharmaceuticals, Inc, Sun Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc, AbbVie Inc., Titan pharmaceuticals, Purdue Pharma and Mallinckrodt Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Opioids Agonist Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Opioids Agonist Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Opioids Agonist Drugs Market by Company
Janssen Pharmaceuticals, Inc
Sun Pharmaceuticals
Sanofi
Johnson & Johnson Services, Inc.
Pfizer Inc
AbbVie Inc.
Titan pharmaceuticals
Purdue Pharma
Mallinckrodt Pharmaceuticals
Hikma Pharmaceuticals PLC
Grünenthal
Endo Pharmaceuticals Inc.
Egalet Corporation
Boehringer Ingelheim
Allergan, Plc
Opioids Agonist Drugs Segment by Type
Fentanyl
Codeine
Morphine
Methadone
Meperidine
Hydrocodone
Opioids Agonist Drugs Segment by Application
Pain Management
Cough Treatment
Diarrhea Treatment
Opioids Agonist Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioids Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Agonist Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Opioids Agonist Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fentanyl
- Codeine
- Morphine
- Methadone
- Meperidine
- Hydrocodone
Applications
- Pain Management
- Cough Treatment
- Diarrhea Treatment
Companies covered
- Janssen Pharmaceuticals, Inc
- Sun Pharmaceuticals
- Sanofi
- Johnson & Johnson Services, Inc.
- Pfizer Inc
- AbbVie Inc.
- Titan pharmaceuticals
- Purdue Pharma
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Grünenthal
- Endo Pharmaceuticals Inc.
- Egalet Corporation
- Boehringer Ingelheim
- Allergan, Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Opioids Agonist Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fentanyl
- 2.2.3 Codeine
- 2.2.4 Morphine
- 2.2.5 Methadone
- 2.2.6 Meperidine
- 2.2.7 Hydrocodone
- 2.3 Opioids Agonist Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pain Management
- 2.3.3 Cough Treatment
- 2.3.4 Diarrhea Treatment
- 2.4 Assumptions and Limitations
3 Opioids Agonist Drugs Breakdown Data by Type
- 3.1 Global Opioids Agonist Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Opioids Agonist Drugs Forecasted Market Size by Type (2027-2032)
4 Opioids Agonist Drugs Breakdown Data by Application
- 4.1 Global Opioids Agonist Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Opioids Agonist Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Opioids Agonist Drugs Market Perspective (2021-2032)
- 5.2 Global Opioids Agonist Drugs Growth Trends by Region
- 5.2.1 Global Opioids Agonist Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Opioids Agonist Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Opioids Agonist Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Opioids Agonist Drugs Market Dynamics
- 5.3.1 Opioids Agonist Drugs Industry Trends
- 5.3.2 Opioids Agonist Drugs Market Drivers
- 5.3.3 Opioids Agonist Drugs Market Challenges
- 5.3.4 Opioids Agonist Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Opioids Agonist Drugs Players by Revenue
- 6.1.1 Global Top Opioids Agonist Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Opioids Agonist Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Opioids Agonist Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Opioids Agonist Drugs Head Office and Area Served
- 6.4 Global Opioids Agonist Drugs Players, Product Type & Application
- 6.5 Global Opioids Agonist Drugs Manufacturers Established Date
- 6.6 Global Opioids Agonist Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Opioids Agonist Drugs Market Size (2021-2032)
- 7.2 North America Opioids Agonist Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Opioids Agonist Drugs Market Size by Country (2021-2026)
- 7.4 North America Opioids Agonist Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Opioids Agonist Drugs Market Size (2021-2032)
- 8.2 Europe Opioids Agonist Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Opioids Agonist Drugs Market Size by Country (2021-2026)
- 8.4 Europe Opioids Agonist Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Opioids Agonist Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Opioids Agonist Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Opioids Agonist Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Opioids Agonist Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Opioids Agonist Drugs Market Size (2021-2032)
- 10.2 South America Opioids Agonist Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Opioids Agonist Drugs Market Size by Country (2021-2026)
- 10.4 South America Opioids Agonist Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Opioids Agonist Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Opioids Agonist Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Opioids Agonist Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Opioids Agonist Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Janssen Pharmaceuticals, Inc
- 12.1.1 Janssen Pharmaceuticals, Inc Company Information
- 12.1.2 Janssen Pharmaceuticals, Inc Business Overview
- 12.1.3 Janssen Pharmaceuticals, Inc Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.1.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio
- 12.1.5 Janssen Pharmaceuticals, Inc Recent Developments
- 12.2 Sun Pharmaceuticals
- 12.2.1 Sun Pharmaceuticals Company Information
- 12.2.2 Sun Pharmaceuticals Business Overview
- 12.2.3 Sun Pharmaceuticals Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.2.4 Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 12.2.5 Sun Pharmaceuticals Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.3.4 Sanofi Opioids Agonist Drugs Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Johnson & Johnson Services, Inc.
- 12.4.1 Johnson & Johnson Services, Inc. Company Information
- 12.4.2 Johnson & Johnson Services, Inc. Business Overview
- 12.4.3 Johnson & Johnson Services, Inc. Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.4.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio
- 12.4.5 Johnson & Johnson Services, Inc. Recent Developments
- 12.5 Pfizer Inc
- 12.5.1 Pfizer Inc Company Information
- 12.5.2 Pfizer Inc Business Overview
- 12.5.3 Pfizer Inc Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.5.4 Pfizer Inc Opioids Agonist Drugs Product Portfolio
- 12.5.5 Pfizer Inc Recent Developments
- 12.6 AbbVie Inc.
- 12.6.1 AbbVie Inc. Company Information
- 12.6.2 AbbVie Inc. Business Overview
- 12.6.3 AbbVie Inc. Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.6.4 AbbVie Inc. Opioids Agonist Drugs Product Portfolio
- 12.6.5 AbbVie Inc. Recent Developments
- 12.7 Titan pharmaceuticals
- 12.7.1 Titan pharmaceuticals Company Information
- 12.7.2 Titan pharmaceuticals Business Overview
- 12.7.3 Titan pharmaceuticals Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.7.4 Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 12.7.5 Titan pharmaceuticals Recent Developments
- 12.8 Purdue Pharma
- 12.8.1 Purdue Pharma Company Information
- 12.8.2 Purdue Pharma Business Overview
- 12.8.3 Purdue Pharma Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.8.4 Purdue Pharma Opioids Agonist Drugs Product Portfolio
- 12.8.5 Purdue Pharma Recent Developments
- 12.9 Mallinckrodt Pharmaceuticals
- 12.9.1 Mallinckrodt Pharmaceuticals Company Information
- 12.9.2 Mallinckrodt Pharmaceuticals Business Overview
- 12.9.3 Mallinckrodt Pharmaceuticals Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.9.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 12.9.5 Mallinckrodt Pharmaceuticals Recent Developments
- 12.10 Hikma Pharmaceuticals PLC
- 12.10.1 Hikma Pharmaceuticals PLC Company Information
- 12.10.2 Hikma Pharmaceuticals PLC Business Overview
- 12.10.3 Hikma Pharmaceuticals PLC Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.10.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio
- 12.10.5 Hikma Pharmaceuticals PLC Recent Developments
- 12.11 Grünenthal
- 12.11.1 Grünenthal Company Information
- 12.11.2 Grünenthal Business Overview
- 12.11.3 Grünenthal Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.11.4 Grünenthal Opioids Agonist Drugs Product Portfolio
- 12.11.5 Grünenthal Recent Developments
- 12.12 Endo Pharmaceuticals Inc.
- 12.12.1 Endo Pharmaceuticals Inc. Company Information
- 12.12.2 Endo Pharmaceuticals Inc. Business Overview
- 12.12.3 Endo Pharmaceuticals Inc. Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.12.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio
- 12.12.5 Endo Pharmaceuticals Inc. Recent Developments
- 12.13 Egalet Corporation
- 12.13.1 Egalet Corporation Company Information
- 12.13.2 Egalet Corporation Business Overview
- 12.13.3 Egalet Corporation Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.13.4 Egalet Corporation Opioids Agonist Drugs Product Portfolio
- 12.13.5 Egalet Corporation Recent Developments
- 12.14 Boehringer Ingelheim
- 12.14.1 Boehringer Ingelheim Company Information
- 12.14.2 Boehringer Ingelheim Business Overview
- 12.14.3 Boehringer Ingelheim Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.14.4 Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio
- 12.14.5 Boehringer Ingelheim Recent Developments
- 12.15 Allergan, Plc
- 12.15.1 Allergan, Plc Company Information
- 12.15.2 Allergan, Plc Business Overview
- 12.15.3 Allergan, Plc Revenue in Opioids Agonist Drugs Business (2021-2026)
- 12.15.4 Allergan, Plc Opioids Agonist Drugs Product Portfolio
- 12.15.5 Allergan, Plc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst